Political Campaigning: Where Scientific and Ethical Arguments Meet Public Policy by McIvor, Emily
WellBeing International 
WBI Studies Repository 
2019 
Political Campaigning: Where Scientific and Ethical Arguments 
Meet Public Policy 
Emily McIvor 
People for the Ethical Treatment of Animals (PETA) 
Follow this and additional works at: https://www.wellbeingintlstudiesrepository.org/anippol 
 Part of the Animal Studies Commons, Other Anthropology Commons, and the Public Policy Commons 
Recommended Citation 
McIvor, E. (2019). Political Campaigning: Where Scientific and Ethical Arguments Meet Public Policy. In 
Animal Experimentation: Working Towards a Paradigm Change (pp. 149-167). Brill. 
This material is brought to you for free and open access 
by WellBeing International. It has been accepted for 
inclusion by an authorized administrator of the WBI 
Studies Repository. For more information, please contact 
wbisr-info@wellbeingintl.org. 
CHAPTER 5 
Political Campaigning: Where Scientific and Ethical 
Arguments Meet Public Policy 
Emily Mcivor 
Science Policy Advisor, People for the Ethical Treatment of Animals 
(PETA). London, United Kingdom 
1 Introduction 
The ambition of the paradigm shift we seek is vast, and the obstacles we face 
are intractable. For anyone opposing the use of non-human animals (herein­
after referred to as animals) in research and testing, the story has been the 
same from the start. Legitimate concern for animals has been all-too-easily 
dismissed as misguided sentimentality, and powerful vested interests have 
claimed scientific, economic, and moral superiority. But the ground is shifting. 
Animal researchers accept the need to provide scientific justification for their 
choices, and the protection of animals is increasingly recognized as a public 
good. Concern among citizens has been translated into hard-and-fast rules, 
and scientific advances have added weight to the growing demand for change. 
In deciding how best to achieve the paradigm shift, the question for animal 
advocates is how to create the greatest change in the shortest time possible. 
This chapter deals with political campaigning at the European Union (Eu) 
level, since the adoption of the first Eu Directive on the protection of animals 
used for scientific purposes, and focuses on the main political developments 
of the past two decades. Historically, much was made of a perceived choice 
between presenting ethical or scientific arguments; both are powerful drivers, 
providing evidence that existing practice is flawed. Other chapters in this Vol­
ume describe aspects of those approaches in detail; similarly, the question of 
whether to focus on the 3Rs or replacement only is also covered elsewhere. In 
this chapter, a pragmatic policy focus is necessary to explore how scientific 
and ethical objectives can be pursued in order to move forward in the politi­
cal arena, making full use of existing structures and creating new opportuni­
ties. The stakes are high. Our vision requires a revolution in science and in the 
way animals are treated. Twenty-first century technology should not depend 
on inhumane practices, just as modern economies should not depend on the 
destruction of the environment or the exploitation of workers. 
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Before proposing future strategies, it is useful to reflect briefly on the cur­
rent situation. In the EU, Directive 2010/63/EU requires Member States to 
apply the 3Rs and encourages the further development of new 3R methods 
and techniques. Research funding programs identify the replacement of an­
imal models as scientific and policy objectives; and several publicly funded 
national centers are now dedicated to developing, validating, and promoting 
alternative methods. The EU Reference Laboratory for Alternatives to Ani­
mal Testing, the European Centre for the Validation of Alternative Methods 
(EURL-ECVAM) has, among its duties and tasks, the remit to coordinate and 
promote the development and use of alternatives to procedures in the areas 
of basic and applied research and regulatory testing (European Parliament, 
2010, Directive 2010/63/EU, Annexvn). Each of these achievements has come 
about because of pressure from citizens and animal advocacy organizations, 
and each has created a momentum of its own so that further progress is inevi­
table. At the same time, the number of animals used in scientific procedures 
in the EU appears to be increasing (Taylor and Rego, 2016); and animal use is 
robustly defended by powerful commercial, academic, and charitable organi­
zations. It is legal to restrain conscious non-human primates (NHPs), so they 
are unable to move at all for long periods, and to poison animals to death by 
applying toxic chemicals to their skin. The scientific revolution is undoubtedly 
underway, and Directive 2010/63/EU identifies animal welfare as a "value of 
the Union" (European Parliament, 2010, Recital 2 ); but current practice has not 
caught up. 
2 The Politics of Animal Experimentation: An Overview 
The development of current European regulatory frameworks can be seen as 
the culmination of a series of historical confrontations between animal us­
ers and advocates (Lyons, 2011 ). By identifying five "critical junctures", includ­
ing the adoption of the United Kingdom's Cruelty to Animals Act in 1876, the 
Royal Commission of 1912, and the adoption of the Animals (Scientific Proce­
dures) Act in 1986 ( UK's transposition of Directive 1986 / 609 EE c; Council of the 
European Communities, 1986), Lyons (2011) traces the evolution, from a largely 
self-regulating, animal user community to the current regulatory regime. The 
relevance to our situation is the analysis of power exercised by those who de­
fend animal use. Through early critical junctures, the power to decide whether 
animal use is justified, to control access to information, and to entrench an es­
tablishment view that the use of animals is essential to medical progress, was 
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firmly placed in the hands of animal users. Only later, with adoption of the 
1986 Act, did the necessity for greater public and political scrutiny gain broad 
support. 
Lyons describes key elements of various positions held, including this anal­
ysis of an animal use ideology (2011, pp. 360-361): 
- It claims that animal welfare is secondary to research goals 
- It considers animal experimentation necessary, and hence permissible, 
in the pursuit of knowledge without immediate or foreseeable human 
benefit 
- It is opposed to utilitarian scrutiny of experimentation proposals 
- It supports professional self-regulation and opposes lay interference in ani-
mal experimentation. 
This is contrasted with an animal welfare belief system: 
- It believes that animal welfare should be given significant weight in policy 
making 
- It believes that proposals for harmful uses of animals should be subject to 
independent utilitarian analysis 
- It considers animal experimentation necessary, and hence permissible, only 
to satisfy urgent and pressing human needs 
- It supports the requirement of lay control to ensure consideration of wider 
public and animal interests. 
And an animal rights philosophy: 
- It posits that all sentient animals have inherent value and share human in­
terest in avoiding suffering 
- It claims that the fundamental rights of protection from torture, killing, and 
enslavement should, therefore, extend beyond the human species to other 
sentient animals 
- It argues for the abolition of animal experimentation. 
In the political arena, the welfare belief system often achieves consensus, and 
politicians can usually gain majority support for measures appearing to bal­
ance competing interests. Furthermore, a welfare agenda represents valuable 
middle-ground when the positions of different interest groups seem so far 
apart as to be irreconcilable. 
Efforts to create a level playing field between industry and civil society 
groups have proved effective at the EU level (Persson, 2007); but in terms of 
numbers alone, leaving aside financial resources, industry and animal user 
groups are better represented than animal advocacy organizations. The 
UK Home Office public consultation on the European Commission's (Ee) 
proposal to revise Directive 86/609/EEC received only 19 responses from animal 
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welfare organizations out of a total of 87 submissions, including 33 from 
academic institutions and 17 from representative bodies (Home Office, 
2010 ). An associated imbalance, concerning access to scientific and politi­
cal decision makers (Lyons, 2011), again risks leaving animal advocacy orga­
nizations severely outdone. However, public opinion is also an important 
element of the debate, and animal advocacy organizations have been effec­
tive in demonstrating that public concern for animals must be taken into 
consideration. 
Polling commissioned by the European Coalition to End Animal Experi­
ments (ECEAE) on the revision of Directive 86/609/EEC-conducted by 
You Gov ( 2009) in the UK, France, Germany, Italy, Sweden and the Czech 
Republic-found that public opinion was not consistent with the EC's legisla­
tive proposal; for example, substantial majorities in all countries surveyed fa­
vored a ban on experiments causing pain or suffering to NHPs (House of Lords, 
2009 ). UK Government surveys exploring attitudes to animal research ( Clem­
ence and Leaman, 2016; Leaman, Latter and Clemence, 2014) note varying de­
grees of public support or opposition, depending on the phrasing of questions. 
There was a slight increase, between 2014 and 20161 in respondents who sup­
ported a ban on the use of any animals in research, from 23% to 26%. The 2016 
survey also found that 59% of people disagreed with the statement "it does not 
bother me if animals are used in scientific research", showing concern for ani­
mals among a clear majority of respondents. The difference, in policy terms, 
between the abolitionist view (represented by the UK's 26%) and a gradualist 
approach is significant; but there is strong agreement (74% of respondents) 
with the statement that more work is needed on alternatives to using animals 
in scientific research. 
In terms of the wider political debate, even though detailed discussions 
about animal care and use tend to emphasize differences among stakeholder 
organizations rather than areas of agreement, promoting the replacement of 
animal procedures is compatible with all three of the belief systems identified 
above. Arguing for the increased uptake of human biology-based technologies 
in biomedical research is not new; but in an era of rapidly developing science 
and divergent opinion concerning other aspects of the debate, its importance 
cannot be overestimated. Because of the need for policy makers to arbitrate 
between opposing views, and the broad appeal of the alternatives' message, 
a major benefit of effective political lobbying is, therefore, ensuring that the 
replacement of animal procedures is promoted to the greatest extent possible. 
This cannot come at the expense of trying to improve conditions for the ani­
mals that are used, but it is a powerful driver towards achieving the paradigm 
shift. 
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The adoption of EU legislation provides multiple access points, and the EC 
encourages interest group participation in order to meet the objective of 
connecting the EU more closely to citizens (Persson, 2007). This objective 
was amply demonstrated during the lengthy process through which Directive 
1986/609/EEC was revised and Directive 2010/63/EU came into being. While 
the revision was underway, the EC adopted an Interinstitutional Agreement on 
Better Law-making (European Commission, 2003, 2003/C321/01), strengthening 
pre-legislative consultation processes and requiring impact assessments. These 
access points, while often appearing to delay the process, ensured valuable evi­
dence was gathered, informing both the legislative proposal and further po­
litical negotiations. Studies, including the scientific Opinion by the European 
Food Safety Authority's Animal Health and Animal Welfare Panel (AHA w), and 
findings from the Technical Expert Working Group convened by the E c, cre­
ated useful evidence and opportunities for further interventions the following 
years. 
The legislative proposal-when finally published in 2008-irritated those 
defending animal use and, although representing a considerable improvement 
on previous legislation, it also failed to satisfy animal advocates. The UK animal 
user community, coming together under the auspices of joint Bioscience Sector 
position papers, identified several areas of concern, including the proposal to 
protect certain invertebrate species, limits on use of NHPs, and burdensome 
bureaucracy. The organizations also raised concerns that the draft Directive 
would undermine UK and European competitiveness, noting that "As well as 
problems with the content, the wording throughout the Directive requires sig­
nificant review for scientific accuracy and internal consistency" (Bioscience 
Sector, 2009, p. 2 ). While generally supporting the application of the 3Rs, the 
groups opposed creation of national structures to assist in the validation of 
new 3R methods, claiming that: "The proposals for National Reference Labora­
tories are unnecessary and infeasible and would not be effective at developing 
alternative methods. They would divert research funding away from research 
which might not only develop alternatives but further benefit biomedical dis­
coveries" (Bioscience Sector, 2009, p. 39 ). 
But by the end of the political negotiation, the new legislation, Directive 
2010/63/EU, included a handful of promising elements, alongside several mea­
sures that are weaker in terms of animal protection, than those contained in 
the EC's original proposal. Central to the achievements for animal protection 
lobbyists is Recital 10 (European Parliament, 2010 ), which specifies that "this 
Directive represents an important step towards achieving the final goal of full 
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replacement of procedures on live animals for scientific and educational pur­
poses as soon as it is scientifically possible to do so." In response to proactive 
EU-wide campaigning for greater prominence to the replacement of animal 
experiments and for the inclusion of basic and applied animal research in the 
remit of EURL ECVAM, EU Member States are now required to promote de­
velopment and use of alternatives, establish a single contact point to receive 
information about new methods, join an EU-wide network of contact points, 
and require new projects to be authorized only when alternatives have been 
considered. Campaigns to ensure regular "thematic reviews" on areas, such as 
the replacement of experiments on NHPs, were partially successful (Article 58); 
and Recital 10 states that the Directive should be "reviewed regularly in light 
of evolving science and animal protection measures" (European Parliament, 
2010 ). Emphasis on the use of existing alternative techniques and the further 
development of new methods is strengthened by requirements for project 
evaluations, increased transparency, and, most importantly, the retrospective 
assessment of all projects using NHPs and projects involving procedures clas­
sified as "severe" (Article 39). 
4 Ending Cosmetics Animal Testing: 20 Years and Counting ... 
Nowhere is the importance of procedural access points and the willingness of 
legislators to respond to the wishes of citizens more visibly demonstrated than 
in the 20-year struggle to end animal testing of cosmetics and the sale of newly 
animal-tested cosmetics ingredients in the EU. Without detailing every one of 
the (numerous) twists and turns it took to see the 2013 ban enter into force, one 
hard-fought measure deserves special mention: the requirement for a full po­
litical negotiation in the event of any attempt to delay implementation of the 
final 2013 deadline. Although the sale ban had been agreed on in 1993 and was 
due to be implemented in 1998, the EC was permitted, under the 6th Amend­
ment to the Cosmetics Directive (European Commission, 1993), to delay it until 
2000 and then to 2002, on the grounds that replacement tests were not fully 
developed. The delays were agreed on through the comitology process, offer­
ing a lower level of access than a full political debate. However, further delays 
were not permitted beyond the 2002 deadline, by which time a new legislative 
proposal was published, triggering a full political negotiation before further 
delays could be adopted. 
The point of interest for campaigners is that within the 7th Amendment 
(European Commission, 2003), new wording deliberately prevented any fur­
ther delay without a legislative proposal being debated and voted upon by 
the European Parliament and Council. The 2009 phase of the sale ban gave no 
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provision for any kind of delay, on any grounds; and the final 2013 phase could 
only be delayed by new legislation. Creating the requirement for another ac­
cess point-a 2013 renegotiation in the event that animal tests had not been 
replaced-was the key compromise that satisfied both industry and animal 
advocates. As the 2013 deadline approached, the EC opted to implement the 
ban and avoid any further accusations that they were ignoring the wishes of 
citizens. However, nothing is safe until full animal replacement is achieved, 
and although animal organizations rightly view an end to cosmetics animal 
testing as a political objective, achievable in the absence of alternatives be­
ing in place, loopholes putting our achievements at risk are relatively easily 
disguised. Perceived ambiguities concerning the terms of the ban have led to 
legal challenges, underlining the need for constant vigilance. Had the wording 
of Article 13 of the Cosmetics Directive been tighter (European Commission, 
2009, Regulation (Ec)1223/2009), we could have avoided the threat of further 
challenges. 
On the day the European Parliament's Environment Committee debated 
their second reading position, a front-page article in the UK's Independent 
newspaper revealed behind-the-scenes lobbying by a major company to en­
sure ambiguity persisted, and loopholes were not closed (Woolf, 2002 ). The 
article was handed to Members of the European Parliament (MEPs) and while 
some unhelpful caveats remained, the final wording saw the Parliament suc­
cessfully overcome opposition from EU Member States and adopt measures 
that would ban animal testing for cosmetics, and phase in the ban on selling 
newly animal-tested cosmetics ingredients ( Osborn, 2002 ). The cosmetics cam­
paign and resulting legislation also emphasize the importance of consensus­
building around the need to replace animal tests. The 1993 legislation triggered 
increased efforts to replace animal methods and resulted in valuable contribu­
tions from industry, Member States, and the EC. EURL ECVAM became a world­
leader in validating alternatives, and the EU entered the twenty-first century 
expressing a clear aspiration to replace outdated, failing animal methods. 
5 REACH, Chemical Testing and Transforming Toxicology 
The political negotiation of Registration, Evaluation, Authorisation and Re­
striction of Chemicals (REACH), the Eu Chemicals Regulation (European Com­
mission, 2006, Regulation (Ee) 1907/2006), forced stakeholders with different 
aims to work together. A direct confrontation between industry (who favored 
lower costs and regulatory burdens) and environmental groups (who called 
for expensive animal testing and rigorous regulatory processes) left animal 
advocates needing to tread carefully. However, the animal protection agenda 
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was in no danger of being ignored. Calculations regarding the number of ani­
mal tests that could be required by REACH-varying initially from 9.5 million 
to 45.8 million (Institute for Environment and Health, 2001)-hit the head­
lines; but there was an associated danger of animal welfare arguments being 
co-opted by those simply wanting to reduce test costs. Politicians, more likely 
to favor environmental concerns, were also those with the strongest policies on 
animal protection; so a simple alignment with industry would have been high­
ly problematic. Policies on data-sharing and transparency helped to forge links 
between animal and environmental groups, but the most important develop­
ment concerned the recognition that animal tests represented outdated sci­
ence. As the discussions progressed, all players acknowledged that because the 
future EU chemicals policy would be dependent on animal testing, it was im­
possible to ignore either the animal welfare or scientific case for replacement. 
Between 2001 and 2003 the tone of the European debate around toxicity 
testing shifted. Publication of the ECEAE report, The Way Forward: A Non­
Animal Testing Strategy for Chemicals (European Coalition to End Animal Ex­
periments, 2003) was pivotal in defining the debate for decades to come. The 
E c EAE argued that in an ideal situation, there would be no need to make a 
choice between saving animals and protecting people. Replacing animal tests 
provided a win/win solution. New non-animal tests could be better, cheaper, 
and faster; and reliance on outdated animal tests would waste money and po­
tentially confound those seeking decisive regulatory action. The conclusion 
of the REACH negotiation in 2006 saw several meaningful animal welfare de­
mands enshrined in legislation, with "promotion of alternative methods for 
assessment of hazards of substances" becoming one of three objectives of the 
legislation, listed in Article 1. 
The political shift, which started with tentative statements from radical 
Green Party politicians about the scientific need to replace animal tests, grew 
to represent the mainstream view of the European Parliament and Council. By 
the time MEPs of the center left had picked up the new rhetoric, a convincing 
case had been made, and at first reading the European Parliament's environ­
mental committee voted for an entirely non-animal testing approach under 
REACH ( Committee on the Environment, Public Health and Food Safety, 2005 ), 
marking a significant call on all concerned to do more to replace animal tests. 
Again, consensus around the need to replace animal methods achieved over­
whelming support, and a central requirement of REACH is that animal testing 
should only be carried out as a last resort. 
The legislative gains enshrined in REACH built on past success concerning 
replacement, including the application and development of 3R methods, as 
mentioned in Directive 1986/609/EEC and required by the 1993 Cosmetics 
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Directive, and broke new ground by requiring rapid updating of legislation in 
response to new methods becoming available. What these legal requirements 
did not do was ensure that regulators and the European Chemicals Agency 
(ECHA) apply the rules without constant pressure from campaigners, culmi­
nating in several rulings against ECHA by the EU Ombudsman for failing to 
meet regulatory requirements relating to avoidance of animal testing (PETA 
UK, 2014; ECHA, 2015). 
6 2001-2003: Paradigm Shift Meets Parliament 
The fifth term of the European Parliament (1999-2004) saw MEPs from across 
the political divide join forces to push the replacement agenda through leg­
islative debates, Reports and Parliamentary Questions. The fact that REACH 
and the 7th Amendment to the Cosmetics Directive were on the Parliamen­
tary agenda at the same time, and the EC was working to revise Directive 
1986/609/EEC, made for more urgency. The EC/Industry collaboration, the Eu­
ropean Partnership for Alternatives to Animal Testing (EPAA), was established 
during this period, providing a forum in which companies could combine re­
sources and expertise and demonstrate their commitment to implementation 
of the 3Rs. The EPAA has achieved a number of notable successes, including 
the study that informed changes to Annex VIII of REACH, ensuring that acute 
toxicity studies, using the dermal route, can be waived in most circumstances 
(EPAA, 2014). 
In the midst of these political activities, the need for an accelerated 
process to achieve international adoption of the Organisation for Economic 
Co-operation and Development ( OECD) Test Guidelines was recognized. The 
International Coalition for Animal Protection in OECD Programs (ICAPO) 
was formed (ICAPO, n.d.), allowing scientific experts working for interna­
tional animal protection organizations, to participate in global efforts to 
implement the 3Rs. The structure of ICAPO has, helpfully, required organiza­
tions to maintain a single point of contact with the OECD and to collaborate 
with each other. To complete the picture, EU Framework Program (FP) fund­
ing decisions were taking a positive direction. Under FP6 (2002-2006), 21 
projects to advance animal-free methods were funded, with a total of over 
€63 million, and contained wording-thanks to the European Parliament­
concerning the need to replace toxicity testing on animals (European Parlia­
ment, 2002, Decision 1513/2002/EC). In this context, during the first years of 
the twenty-first century, several advances were made, the results of which are 
still playing out. 
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7 Post-2010/63/EU: E U  Lobbying and the Global Challenge 
During the negotiation of Directive 2010/63/EU, information about the in­
tentions of industry and the animal user community crept into the pub­
lic domain. In the absence of replacement science successfully displacing 
animal research, the future for animals could look very bleak indeed. In 
2009, the UK House of Lords Select Committee on the European Union Sub­
Committee D (Environment and Agriculture) held an inquiry and reported 
to Parliament (HL 164 2009-2010 ). During the evidence sessions, questions 
were posed about the potential for higher welfare standards in the Eu to 
drive animal use abroad. While there was clear evidence that an EU re­
search base holds several advantages for companies, several contributions 
were worrying. 
Evidence presented in the Memorandum by the Bioscience Sector (House 
of Lords, 2009) notes the existence of "substantial competition from coun­
tries, such as China, India, and Singapore in developing infrastructure to 
undertake animal research, which includes not just routine toxicity tests but 
also R & D" (p. 21); and states that "commercial investment [is] increasing 
faster in countries outside the EU, such as the us ,  China and India" (p. 19). 
During the oral evidence session, industry representatives described the 
experience that "most major pharmaceutical companies are now investing 
in Asia" (p. 43), with decisions being "influenced very strongly, particularly, 
by access to non-human primates and developing the Asian market with 
particular reference to China" (p. 43). One representative went on to de­
scribe new facilities in Shanghai, which will focus on cancer research and 
collaboration with a Chinese institution dedicated to constructing a specific 
NHP facility. 
The view that higher EU welfare standards are unlikely to contribute in 
the short term to this shift is broadly supported, but the expectation of in­
dustry is that growing markets and longer-term projections are contributing 
to the expansion of animal facilities in countries not governed by EU stan­
dards. The fear is not so much that companies will fail to keep pace with, 
for example, EU standards of housing and care, but that in countries with 
less rigorous legislation, less attention will be paid to severity limits, report­
ing, and transparency. This global expansion does not, however, mean that 
EU political campaigning is any less important. Increased scientific scrutiny, 
such as that required by European legislation, along with funding for the de­
velopment of alternatives, is driving global change. We cannot protect NHP 
in Chinese research facilities, but we can hold the science behind NHP use to 
account. 
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8 The EC's Scientific Committee Opinions on NHP Use, 2009 and 2017 
Use of NHPs in the EU is highly controversial. Years of public campaigning has 
raised awareness of NHP suffering and sentience (Jennings, 2010 ); and the 2007 
European Parliamentary Declaration, which called for a timetable for replac­
ing all use of NHPs (European Parliament, 2007, P6_TA(2007)0407) led to the 
inclusion of proposals to limit NHP use in the EC's legislative proposal of 2008. 
Alongside this, the EC requested a series of Opinions from its scientific com­
mittees concerning the potential to replace NHP use. 
Animal advocates have, repeatedly, found the process by which the Opinions 
have been formulated frustrating and biased. Contributors tend to be N HP users 
rather than biomedical researchers who use non-animal methods. In the most 
recent Opinion, released by the Scientific Committee on Health Environmental 
and Emerging Risks (SCHEER) (SCHEER, 2017), the Committee argues in favor 
of continued NHP use, while failing to acknowledge key reviews on the ineffec­
tiveness of NHPs as a model for humans or reviews on advances in alternative 
animal-free methods. Nevertheless, the Committee made a handful of recom­
mendations, including that systematic reviews should be undertaken and the 
"psychological effect" on N HP s should be better assessed ( though this latter rec­
ommendation could lead to further research on N HP laboratory welfare). 
g The Citizens' Initiative: Stop Vivisection 
In this context, it is not hard to see why campaigners have continued to call 
for an outright ban on all animal experiments. The Lisbon Treaty of 2009 in­
troduced a process by which European citizens can initiate activity by the EC, 
including proposals for new legislation, if a petition receives one million sig­
natures collected in seven EU Member States within one year (the European 
Citizens' Initiative, European Commission, 2011). The third successful Citizens' 
Initiative, Stop Vivisection, registered in 2012, called on the EC to "abrogate di­
rective 2010/63/EU on the protection of animals used for scientific purposes 
and to present a new proposal that does away with animal experimentation 
and instead makes compulsory the use-in biomedical and toxicological re­
search-of data directly relevant for the human species" (European Citizens' 
Initiative, 2016). The Citizens' Initiative demonstrated, again, EU-wide support 
for ending the use of animals in research and testing, raised awareness among 
policy makers, and generated new commitments from the EC. The European 
Parliament hearing on the Citizens' Initiative gave MEPs the opportunity to lis­
ten to arguments first-hand and question experts (European Parliament, 2015). 
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The EC's 2015 Communication responding to Stop Vivisection (C(2015) 3773) 
identified four action points: 
(1) Acceleration of progress in the 3Rs through knowledge sharing 
(2) Development, validation, and implementation of new alternative 
approaches 
(3) Enforcement of compliance with the 3Rs principle and alignment of rel-
evant sector legislation 
(4) Engagement in a dialogue with the scientific community. 
The EC's response concluded by welcoming "the mobilisation of citizens in 
support of animal welfare" stating that "the Citizens' Initiative has provided 
an opportunity to critically examine how the EU can reinforce its efforts in 
moving from animal to non-animal based research and testing" (European 
Commission, 2015, p. 10 ). However, there is no evidence that relevant decision­
making bodies, such as Member State National Committees, referred to in Di­
rective 2010/63/EU, are making the necessary adjustments. 
Action 4 committed the EC to organize a scientific conference titled Non­
Animal Approaches - The Way Forward, which, although supported by a 
wider-than-usual audience of stakeholders, was boycotted by the organizers 
of the Stop Vivisection Citizens' Initiative, who later made a complaint to the 
EU Ombudsman, considering that "the [European] Commission had given 
an inadequate response to the initiative and the detailed proposals put for­
ward in the context of the initiative". The Ombudsman rejected the complaint 
(Eu Ombudsman, 2017); but the substance of the Initiative remains active, 
and is an important milestone for policy makers at all levels of EU decision 
making. 
10 Conclusion 
Scientific progress does not necessarily equate to changes in practice, in public 
policy, or in legislation; but political progress can drive science. For this rea­
son alone, effective political strategies are essential. The paradigm shift can 
be accelerated by improvements in transparency, reporting, and protection of 
animals as well as by increasing levels of scientific scrutiny, funding, and po­
litical will. Experience gained at the EU level demonstrates that when public 
opinion-backed by convincing evidence and practical proposals-can be ef­
fectively presented, policy makers are required to balance competing interests 
and promote workable solutions. In the field of research on animals, this often 
results in increased efforts to replace animal experiments. Public opinion sur­
veys indicate that legislators have not yet created laws that adequately address 
citizens' concerns; but continuing public and political pressure has ensured 
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new initiatives are likely and further access points, in terms of influencing the 
regulatory agenda, are open to advocacy groups. 
Developing a coherent political strategy on the basis of either science or ani­
mal protection alone is fraught with difficulties. Heated debate, and regulatory 
systems attempting to balance animal suffering with expected outcomes have 
forced animal advocates into the scientific arena and scientists to respond to 
welfare requirements. Those campaigning for a paradigm shift are gaining sci­
entific weight and credibility, and new technologies are unstoppable. 
So, what will end the use of animals in experiments in the shortest pos­
sible time? Using the experience gained over the past twenty years of EU-level 
campaigning, it seems sensible to accept that widely different approaches and 
organizations all have their place. Welfare advocates who work only with in­
dustry can achieve a great deal; the promoters of the Citizens' Initiative, Stop 
Vivisection, caused the E C  to set new goals and attempt to create consensus 
between stakeholders holding radically different views, and EU-level coali­
tions of national advocacy groups, together with a handful of international 
organizations, through dogged scrutiny of implementation procedures, main­
tain public and political pressure. The need for legislators and regulators to 
demonstrate a willingness to hear the views of a range of stakeholders has al­
lowed animal advocates to find a voice at all levels of political processes and to 
work with other campaign groups, industry, and academia to promote shared 
objectives. 
The experience of political campaigning described above is offered in the 
hope that the paradigm shift happens sooner rather than later. The follow­
ing overview of the points described above and lessons learned may also be 
of use: 
Political Campaigning: 
- Make use of all procedural access points, remembering that early interven­
tion works best. 
- Work across political divides and with all stakeholders to understand the 
full range of opinions and differing viewpoints. 
- Join expert groups, share expertise, and try to avoid duplicating the work of 
other, similar organizations. 
- Understand the agenda of your opponents and check the meaning of word­
ing that seems unclear. Loopholes can be avoided if spotted early enough. 
- Create new access points. Always work for regular reviews, reports, and fur­
ther studies. 
- Find ways to increase transparency. From ensuring all animals are count­
ed to sophisticated prospective and retrospective reviews, transparency is 
essential. 
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Appreciate the work of consensus-based entities. Where there is consensus, 
meaningful progress should be achievable. 
Amplifying Our Message: 
Animal advocacy organizations working together are more likely to suc­
ceed. We have seen this through I CAPO and in the political arena. Sharing 
material early on and avoiding duplication is more likely to ensure initia­
tives are successful. 
Formulating joint positions with other organizations, such as environment, 
health, patient, and industry groups, amplifies our message. 
Coalitions and umbrella groups are helpful but need to demonstrate the ex­
tent of their supporter base, for example, by directly linking politicians with 
national organizations and the citizens they represent. 
The question of global versus national or regional campaigning answers itself. 
We need to work at every level, in every forum, using all peaceful, evidence­
based, effective means available to us. From handing out leaflets in the street 
to funding studies by researchers to expose failing animal models of dis­
ease, every contribution is valuable and is helping to achieve the paradigm 
shift. 
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